Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Key Highlights
- ➤$22.3 million BioThrax delivery-order modification awarded to Emergent BioSolutions (EBS)
- ➤$7.4 million first delivery begins this year; remaining deliveries expected in 2027
- ➤BioThrax supplies U.S. military anthrax pre-exposure prophylaxis under existing IDIQ contract
- ➤Emergent received approximately $24 million CYFENDUS contract modification in August 2026
Expert Statements
Paul Williams, Senior vice president, head of products business, global government and public affairs at Emergent
“We’re pleased to continue supporting the Department of War’s efforts to maintain preparedness against critical biological threats like anthrax”
Paul Williams, Senior vice president, head of products business, global government and public affairs at Emergent
“Delivering dependable access to BioThrax(®) helps protect our nation’s service members who have an elevated risk of anthrax exposure.”
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax(®) (Anthrax Vaccine Adsorbed) to the U.S. Department of War
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax(®) (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027.
Get started
Create a free account to read the full story.